PHARMACEUTICAL COMPOSITIONS OF FUMARIC ACID ESTERS

1 .- 58 . (canceled)

59 . A method of treating a disease in a patient, comprising administering to the patient having the disease a dosage form,

wherein the disease is an autoimmune disease,

wherein the dosage form is a tablet comprising:

(a) about 1 mg to about 600 mg (N,N-diethylcarbamoyl)methyl methyl (2E)but-2-ene-1, 4-dioate; and

(b) one or more compounds of Formulae (I), (II), (III), (IV), (V), (VI), (XIII), or (XV):

N,N-diethyl-2-hydroxyacetamide, and salts of any of the foregoing, wherein:

each of R 1 through R 4 is independently chosen from hydrogen, methyl and (N,N-diethylcarbamoyl)methyl;

each R 5 and R 7 is independently chosen from hydrogen, methyl, and (N,N-diethylcarbamoyl)methyl;

Y is chosen from O, S, NH and NR 8 ;

R 6 is chosen from hydrogen, lower alkyl, substituted lower alkyl, aryl, and substituted aryl;

R 8 is chosen from lower alkyl;

each of R 9 and R 10 is independently chosen from hydrogen, methyl, and (N,N-diethylcarbamoyl)methyl;

each of R 11 and R 12 is independently chosen from hydrogen, methyl, and (N,N-diethylcarbamoyl)methyl;

each of R 13 and R 14 is independently chosen from hydrogen, methyl, and (N,N-diethylcarbamoyl)methyl;

Q is —O—, —S—, —NH—, —N(R 17 )— or —C(R 18 ) 2 —;

each of R 15 and R 16 is independently chosen from hydrogen, methyl, and (N,N-diethylcarbamoyl)methyl;

R 17 is (N,N-diethylcarbamoyl)methyl or alkyl;

each R 18 is independently hydrogen or alkyl;

each of R 37 and R 31 is independently chosen from hydrogen, methyl, and (N,N-diethylcarbamoyl)methyl;

R 41 is (N,N-diethylcarbamoyl)methyl;

R 42 is chosen from hydrogen, ethyl, and (N,N-diethylcarbamoyl)methyl;

wherein the one or more compounds of Formulae (I), (II), (III), (IV), (V), (VI), (XIII), and (XV), and N,N-diethyl-2-hydroxyacetamide is present in a combined total amount of 0.001% to 3% by weight based on total weight of the (N,N-diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate, and the one or more compounds of Formula (I) is present in a combined amount of less than 1.4% by weight based on total weight of the (N,N-diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate.

60 . The method of claim 59 , wherein any one of the one or more compounds of Formulae (I), (II), (III), (IV), (V), (VI), (XIII), and (XV), and N,N-diethyl-2-hydroxyacetamide is present in the dosage form in an amount of less than 0.1% by weight based on total weight of the (N,N-diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate.

61 . The method of claim 59 , wherein the one or more compounds of Formulae (I), (II), (III), (IV), (V), (VI), (XIII), and (XV), and N,N-diethyl-2-hydroxy acetamide is present in a combined total amount of less than 2% by weight based on total weight of the (N,N-diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate.

62 . The method of claim 59 , wherein the one or more compounds of Formulae (I), (II), (III), (IV), (V), (VI), (XIII), and (XV) is selected from:

Formula (I) compounds 1,2-bis((N,N-diethylcarbamoyl)methoxycarbonyl)-3,4-bis(methoxycarbonyl)cyclobutane; 1,3-((N,N-diethylcarbamoyl)methoxycarbonyl)-2,4-bis(methoxycarbonyl)cyclobutane; 1-(N,N-diethylcarbamoyl)methoxycarbonyl-2-methoxycarbonylcyclobutane-3,4-dicarboxylic acid; 1,2-((N,N-diethylcarbamoyl)methoxycarbonyl)cyclobutane-2,3-dicarboxylic acid; 1,3-((N,N-diethylcarbamoyl)methoxycarbonyl)cyclobutane-2,4-dicarboxylic acid; 1,2-bis(methoxycarbonyl)cyclobutane-3,4-dicarboxylic acid; 1,3-bis(methoxycarbonyl)cyclobutane-2,4-dicarboylic acid; cyclobutane-1,2,3,4-tetracarboxylic acid; 1,2-((N,N-diethylcarbamoyl)methoxycarbonyl)-3-methoxycarbonylcyclobutane-4-carboxylic acid; 1,2-bis(methoxycarbonyl)cyclobutane-3,4-dicarboxylic acid; 1,2-bis(methoxycarbonyl)-3-((N,N-diethylcarbamoyl)methoxycarbonyl)cyclobutane-4-carboxylic acid; 1,2-((N,N-diethylcarbamoyl)methoxycarbonyl)-3-(methoxycarbonyl)cyclobutane-4-carboxylic acid; 1-((N,N-diethylcarbamoyl)methoxycarbonyl)-2,3-bis(methoxycarbonyl)cyclobutane-4-carboxylic acid; 1-((N,N-diethylcarbamoyl)methoxycarbonyl)cyclobutane-2,3,4-tricarboxylic acid; and 1-(methoxycarbonyl)cyclobutane-2,3,4-tricarboxylic acid;

Formula (II) compounds (N,N-diethylcarbamoyl)methyl-methyl-hydroxysuccinate; methyl-hydroxysuccinic mono-acid; (N,N-diethylcarbamoyl)methyl-hydroxysuccinic mono-acid; hydroxysuccinic acid; (N,N-diethylcarbamoyl)methyl-methyl-mercaptosuccinate; methylmercaptosuccinic mono-acid; (N,N-diethylcarbamoyl)methyl-mercaptosuccinic mono-acid; mercaptosuccinic acid; (N,N-diethylcarbamoyl)methyl-methyl-aminosuccinate; methylaminosuccinic mono-acid; (N,N-diethylcarbamoyl)methyl-aminosuccinic mono-acid; and aminosuccinic acid;

Formula (III) compounds cis-(N,N-diethylcarbamoyl)methyl-methyl oxirane dicarboxylate; cis-(methoxycarbonyl)oxirane carboxylic mono-acid; cis-(N,N-diethylcarbamoyl)methoxycarbonyl oxirane carboxylic mono-acid; cis-oxirane 2,3-dicarboxylic acid; trans-(N,N-diethylcarbamoyl)methyl-methyl oxirane dicarboxylate; trans-(methoxycarbonyl)oxirane carboxylic mono-acid; trans-(N,N-diethylcarbamoyl)methoxycarbonyl oxirane carboxylic mono-acid; and trans-oxirane 2,3-dicarboxylic acid;

Formula (IV) compounds (N,N-diethylcarbamoyl)methyl-methyl-succinate; methylsuccinic mono-acid; ((N,N-diethylcarbamoyl)methyl)succinic mono-acid; and succinic acid;

Formula (V) compounds (N,N-diethylcarbamoyl)methyl-methyl-2,3-dihydroxysuccinate; methyl-2,3-dihydroxysuccinic mono-acid; (N,N-diethylcarbamoyl)methyl-2,3-dihydroxysuccinic mono-acid; and 2,3-dihydroxysuccinic acid (tartaric acid);

Formula (VI) compounds wherein: Q is —O—, and each R 15 and R 16 is methyl; Q is —O—, and each R 15 and R 16 is H; Q is —O—, and each R 15 and R 16 is (N,N-diethylcarbamoyl)methyl; Q is —O—, R 15 is H, and R 16 is methyl; Q is —O—, R 15 is H, and R 16 is (N,N-diethylcarbamoyl)methyl; Q is —O—, R 15 is methyl, and R 16 is (N,N-diethylcarbamoyl)methyl; Q is —S—, and each of R 15 and R 16 is methyl; Q is —S—, and each of R 15 and R 16 is H; Q is —S—, and each of R 15 and R 16 is (N,N-diethylcarbamoyl)methyl; Q is —S—, R 15 is H, and R 16 is methyl; Q is —S—, R 15 is H, and R.sup.16 is (N,N-diethylcarbamoyl)methyl; Q is —S—, R 15 is methyl, and R 16 is (N,N-diethylcarbamoyl)methyl; Q is —NH—, and each of R 15 and R 16 is methyl; Q is —NH—, and each of R 15 and R 16 is H; Q is —NH—, and each of R 15 and R 16 is (N,N-diethylcarbamoyl)methyl; Q is —NH—, R 15 is H, and R 16 is methyl; Q is —NH—, R 15 is H, and R 16 is (N,N-diethylcarbamoyl)methyl; Q is —NH—, R 15 is methyl, and R 16 is (N,N-diethylcarbamoyl)methyl; Q is —NMe-, and each of R 15 and R 16 is methyl; Q is —NMe-, and each of R 15 and R 16 is H; Q is —NMe-, and each of R 15 and R 16 is (N,N-diethylcarbamoyl)methyl; Q is —NMe-, R 15 is H, and R 16 is methyl; Q is —NMe-, R 15 is H, and R 16 is (N,N-diethylcarbamoyl)methyl; Q is —NMe-, R 15 is methyl, and R 16 is (N,N-diethylcarbamoyl)methyl; Q is —CH 2 —, and each R 15 and R 16 is methyl; Q is —CH 2 —, and each R 15 and R 16 is H; Q is —CH 2 —, and each R 15 and R 16 is (N,N-diethylcarbamoyl)methyl; Q is —CH 2 —, R 15 is H, and R 16 is methyl; Q is —CH 2 —, R 15 is H, and R 16 is (N,N-diethylcarbamoyl)methyl; and Q is —CH 2 —, R 15 is methyl, and R 16 is (N,N-diethylcarbamoyl)methyl;

Formula (XIII) compounds (N,N-diethylcarbamoyl)methyl methyl maleate, (N,N-diethylcarbamoyl)methyl maleic acid, bis((N,N-diethylcarbamoyl)methyl) maleate, dimethyl maleate, methyl maleate, and maleic acid; and

Formula (XV) compounds (2E)-3-(((N,N-diethylcarbamoyl)methyl)oxycarbonyl)prop-2-enoic acid; (N,N-diethylcarbamoyl)methyl ethyl (2E)but-2-ene-1,4-dioate; and bis(N,N-diethylcarbamoyl)methyl(2E)but-2-ene-1,4-dioate; isomers of any of the foregoing compounds and salts of any of the foregoing compounds.

63 . The method of claim 59 , wherein the dosage form comprises an opaque layer that is free of the (N,N-diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate.

64 . The method of claim 63 , wherein the opaque layer is a coating.

65 . The method of claim 63 , wherein the opaque layer comprises a gelatin capsule comprising an opaque material.

66 . The method of claim 63 , wherein the dosage form is enclosed in a package that limits exposure of the dosage form to ambient light.

67 . The method of claim 66 , wherein the package is a bottle comprising an opaque polymer.

68 . The method of claim 66 , wherein the package is a blister pack comprising metal foil, an opaque polymer or a combination thereof.

69 . The method of claim 59 , wherein (N,N-diethylcarbamoyl)methyl methyl (2E)but-2-ene-1, 4-dioate is present in the dosage form at about 300 mg to about 600 mg.

70 . The method of claim 59 , wherein (N,N-diethylcarbamoyl)methyl methyl (2E)but-2-ene-1, 4-dioate is present in the dosage form at about 400 mg to about 500 mg.

71 . The method of claim 59 , wherein the dosage form comprises one or more compounds of Formula (II), and wherein the dosage form is substantially free of materials that promote addition reactions of the (N,N-diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate.

72 . The method of claim 59 , wherein the dosage form comprises the one or more compounds of Formula (II), wherein the dosage form is substantially free of materials that promote addition reactions of the (N,N-diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate.

73 . The method of claim 59 , wherein the dosage form comprises the one or more compounds of Formula (III), wherein the one or more compounds of Formula (III) is (N,N-diethylcarbamoyl)methyl methyl oxirane-2,3-dicarboxylate.

74 . The method of claim 59 , wherein the dosage form comprises the one or more compounds of Formula (IV), wherein the dosage form is substantially free of any compound capable of facilitating the reduction of the double bond of (N,N-diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate.

75 . The method of claim 59 , wherein the dosage form comprises the one or more compounds of Formula (VI), wherein the dosage form is substantially free of materials that are capable of reacting with (N,N-diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate to form Diels-Alder products.

76 . The method of claim 59 , wherein the autoimmune disease is multiple sclerosis.

77 . The method of claim 59 , wherein the autoimmune disease is psoriasis.

78 . The method of claim 77 , wherein the autoimmune disease is plaque psoriasis.